NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies

Pharmacological Research

Volumn 56, Issue 1, 2007, Pages 65-69

  Lambiase, Alessandro ^a   Coassin, Marco ^a   Sposato, Valentina ^b   Micera, Alessandra ^a,c   Sacchetti, Marta ^a   Bonini, Stefano ^a   Aloe, Luigi ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CNR   (Italy)

^c IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Antibodies; Corneal ulcer; Nerve growth factor; Side effects; Topical treatment

Indexed keywords

EYE DROPS; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA ULCER; EYE DISCOMFORT; FEMALE; FOLLOW UP; HUMAN; KERATITIS; KERATOPATHY; MALE; NEUROTROPHIC KERATOPATHY; PHOTOPHOBIA; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANIMALS; ANTIBODIES; CORNEAL ULCER; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NERVE GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34347237872     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.03.007     Document Type: Article

References (34)

1. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237 (1987) 1154-1162
2. Micera A., Lambiase A., Aloe L., Bonini S., Levi-Schaffer F., and Bonini S. Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. Cytokine Growth Factor Rev 15 (2004) 411-417
3. Chao M.V., Rajagopal R., and Lee F.S. Neurotrophin signalling in health and disease. Clin Sci (Lond) 110 (2006) 167-173
4. Allen S.J., and Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 110 (2006) 175-191
5. Apfel S. Clinical applications of neurotrophic factors (1997), Lippincott-Raven, Philadelphia
6. Kim D.H., Gutin P.H., Noble L.J., Nathan D., Yu J.S., and Nockels R.P. Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat. Neuroreport 7 (1996) 2221-2225
7. Holtzman D.M., Sheldon R.A., Jaffe W., Cheng Y., and Ferriero D.M. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 39 (1996) 114-122
8. Chaturvedi R.K., Shukla S., Seth K., and Agrawal A.K. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci Lett 398 (2006) 44-49
9. Apfel S.C., Schwartz S., Adornato B.T., Freeman R., Biton V., Rendell M., et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. Jama 284 (2000) 2215-2221
10. McArthur J.C., Yiannoutsos C., Simpson D.M., Adornato B.T., Singer E.J., Hollander H., et al., AIDS Clinical Trials Group Team 291. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology 54 (2000) 1080-1088
11. Eriksdotter Jonhagen M., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9 (1998) 246-257
12. Olson L., Nordberg A., von Holst H., Backman L., Ebendal T., Alafuzoff I., et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4 (1992) 79-95
13. Olson L., Backlund E.O., Ebendal T., Freedman R., Hamberger B., Hansson P., et al. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch Neurol 48 (1991) 373-381
14. Carmignoto G., Maffei L., Candeo P., Canella R., and Comelli C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J Neurosci 9 (1989) 1263-1272
15. Turner J.E., and Delaney R.K. Retinal ganglion cell response to axotomy and nerve growth factor in the regenerating visual system of the newt (Notophthalmus viridescens): an ultrastructural morphometric analysis. Brain Res 171 (1979) 197-212
16. Siliprandi R., Canella R., and Carmignoto G. Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia. Invest Ophthalmol Vis Sci 34 (1993) 3232-3245
17. Lambiase A., Centofanti M., Micera A., Manni G.L., Mattei E., De Gregorio A., et al. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol 235 (1997) 780-785
18. Lenzi L., Coassin M., Lambiase A., Bonini S., Amendola T., and Aloe L. Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. Vision Res 45 (2005) 1491-1500
19. Lambiase A., Bonini S., Aloe L., Rama P., and Bonini S. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol 118 (2000) 1446-1449
20. Landi F., Aloe L., Russo A., Cesari M., Onder G., Bonini S., et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med 139 (2003) 635-641
21. Bernabei R., Landi F., Bonini S., Onder G., Lambiase A., Pola R., et al. Effect of topical application of nerve-growth factor on pressure ulcers. Lancet 354 (1999) 307
22. Tuveri M., Generini S., Matucci-Cerinic M., and Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 356 (2000) 1739-1740
23. Lambiase A., Rama P., Bonini S., Caprioglio G., and Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 338 (1998) 1174-1180
24. Bonini S., Lambiase A., Rama P., Caprioglio G., and Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 107 (2000) 1347-1351 discussion 1351-2
25. Pushker N., Dada T., Vajpayee R.B., Gupta V., Aggrawal T., and Titiyal J.S. Neurotrophic keratopathy. Clao J 27 (2001) 100-107
26. Lambiase A., Rama P., Aloe L., and Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol 10 (1999) 270-276
27. Bocchini V., and Angeletti P.U. The nerve growth factor: purification as a 30,000-molecular-weight protein. Proc Natl Acad Sci USA 64 (1969) 787-794
28. Blake C.R., Cervantes-Castaneda R.A., Macias-Rodriguez Y., Anzoulatous G., Anderson R., and Chayet A.S. Comparison of postoperative pain in patients following photorefractive keratectomy versus advanced surface ablation. J Cataract Refract Surg 31 (2005) 1314-1319
29. Faulkner W., and Varley G. Corneal diagnostic technique. In: Krachmer J., Mannis M., and Holland E. (Eds). Cornea: fundamentals of cornea and external disease (1997), St. Louis, Mosby 275-281
30. Dicou E., Hurez D., and Nerriere V. Natural autoantibodies against the nerve growth factor in autoimmune diseases. J Neuroimmunol 47 (1993) 159-167
31. Gorin P.D., and Johnson Jr. E.M. Effects of exposure to nerve growth factor antibodies on the developing nervous system of the rat: an experimental autoimmune approach. Dev Biol 80 (1980) 313-323
32. Poletaev A.B., Morozov S.G., Gnedenko B.B., Zlunikin V.M., and Korzhenevskey D.A. Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders. Autoimmunity 32 (2000) 33-38
33. Barde Y.A. The nerve growth factor family. Prog Growth Factor Res 2 (1990) 237-248
34. Dicou E., and Nerriere V. Evidence that natural autoantibodies against the nerve growth factor (NGF) may be potential carriers of NGF. J Neuroimmunol 75 (1997) 200-203